Immunotherapy for acute kidney injury

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 323-334

  Berry, Miriam ^a   Clatworthy, Menna R ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

acute kidney injury; acute tubular; damage associated molecular pattern; delayed graft function; ecrosis; IL 1 ; inflammasome; neutrophil recruitment

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CRYOPYRIN; CYCLOSPORIN A; ENLIMOMAB; FENOLDOPAM; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; ODULIMOMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; THEOPHYLLINE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADAPTIVE IMMUNITY; BLOOD PRESSURE; CELL DEATH; CHRONIC DISEASE; COMPLEMENT ACTIVATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY CELL; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MULTICENTER STUDY (TOPIC); NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; T CELL DEPLETION;

ANIMALS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CARRIER PROTEINS; HUMANS; IMMUNOTHERAPY; INFLAMMASOMES; INTERLEUKIN-1BETA; KIDNEY TRANSPLANTATION; KIDNEY TUBULAR NECROSIS, ACUTE; NEUTROPHIL INFILTRATION; NEUTROPHILS; RENAL CIRCULATION; SEPSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858327085     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.175     Document Type: Review

References (116)

1. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am. J. Med. 74(2), 243-248 (1983). (Pubitemid 13192180)
2. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am. J. Kidney Dis. 39(5), 930-936 (2002). (Pubitemid 34454211)
3. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units - causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit. Care Med. 24(2), 192-198 (1996). (Pubitemid 26065324)
4. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N. Engl. J. Med. 334(22), 1448-1460 (1996). (Pubitemid 126590563)
5. Solez K, Morel-Maroger L, Sraer JD. The morphology of 'acute tubular necrosis' in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 58(5), 362-376 (1979). (Pubitemid 10234879)
6. Venkatachalam MA, Bernard DB, Donohoe JF, Levinsky NG. Ischemic damage and repair in the rat proximal tubule: differences among the S1, S2, and S3 segments. Kidney Int. 14(1), 31-49 (1978). (Pubitemid 8396236)
7. Diamond JR, Yoburn DC. Nonoliguric acute renal failure associated with a low fractional excretion of sodium. Ann. Intern. Med. 96(5), 597-600 (1982). (Pubitemid 12111115)
8. Spurney RF, Fulkerson WJ, Schwab SJ. Acute renal failure in critically ill patients: prognosis for recovery of kidney function after prolonged dialysis support. Crit. Care Med. 19(1), 8-11 (1991).
9. Howard RJ, Pfaff WW, Brunson ME, et al. Increased incidence of rejection in patients with delayed graft function. Clin. Transplant. 8(6), 527-531 (1994). (Pubitemid 24361557)
10. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 64(7), 945-947 (1997). (Pubitemid 27446755)
11. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 46(2), 223-228 (1988).
12. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int. 59(5), 1626-1640 (2001). (Pubitemid 32336778)
13. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1), 1-13 (1989). (Pubitemid 20177564)
14. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994). (Pubitemid 24140436)
15. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 8(4), 279-289 (2008). (Pubitemid 351432799)
16. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13(7), 851-856 (2007). (Pubitemid 47038190)
17. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
18. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 87(6), 2095-2147 (1996). (Pubitemid 26086851)
19. Armstrong DA, Major JA, Chudyk A, Hamilton TA. Neutrophil chemoattractant genes KC and MIP-2 are expressed in different cell populations at sites of surgical injury. J. Leukoc. Biol. 75(4), 641-648 (2004). (Pubitemid 38405655)
20. Springer TA. Adhesion receptors of the immune system. Nature 346(6283), 425-434 (1990).
21. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314(5806), 1792-1795 (2006). (Pubitemid 44969094)
22. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330(6002), 362-366 (2010).
23. Schroder K, Tschopp J. The inflammasomes. Cell 140(6), 821-832 (2010).
24. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201(7), 1135-1143 (2005). (Pubitemid 40524681)
25. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 28, 321-342 (2010).
26. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am. J. Physiol. Renal Physiol. 281(5), F887-F899 (2001).
27. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc. Nephrol. 21(11), 1878-1890 (2010).
28. Leemans JC, Stokman G, Claessen N, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Invest. 115(10), 2894-2903 (2005). (Pubitemid 41434417)
29. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Invest. 117(10), 2847-2859 (2007). (Pubitemid 47529615)
30. Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl Acad. Sci. USA 106(48), 20388-20393 (2009).
31. Melnikov VY, Faubel S, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J. Clin. Invest. 110(8), 1083-1091 (2002). (Pubitemid 35215889)
32. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1- deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 66(6), 2202-2213 (2004). (Pubitemid 41115283)
33. Liu HF, Liang D, Wang LM, et al. Effects of specific interleukin-1beta- converting enzyme inhibitor on ischemic acute renal failure in murine models. Acta Pharmacol. Sin. 26(11), 1345-1351 (2005). (Pubitemid 41607007)
34. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol. Dial. Transplant. 21(5), 1231-1239 (2006).
35. Ferenbach DA, Ramdas V, Spencer N, et al. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. Mol. Ther. 18(9), 1706-1713 (2010).
36. Ko GJ, Boo CS, Jo SK, Cho WY, Kim HK. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol. Dial. Transplant. 23(3), 842-852 (2008). (Pubitemid 351767562)
37. Lee S, Huen S, Nishio H, et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22(2), 317-326 (2011).
38. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int. 66(2), 486-491 (2004). (Pubitemid 38981983)
39. Kelly KJ, Williams WW Jr, Colvin RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J. Clin. Invest. 97(4), 1056-1063 (1996). (Pubitemid 26070586)
40. Doi K, Okamoto K, Negishi K, et al. Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am. J. Pathol. 168(5), 1413-1424 (2006).
41. Wu X, Guo R, Wang Y, Cunningham PN. The role of ICAM-1 in endotoxin-induced acute renal failure. Am. J. Physiol. Renal Physiol. 293(4), F1262-F1271 (2007). (Pubitemid 47583961)
42. Thornton MA, Winn R, Alpers CE, Zager RA. An evaluation of the neutrophil as a mediator of in vivo renal ischemic-reperfusion injury. Am. J. Pathol. 135(3), 509-515 (1989). (Pubitemid 19246209)
43. Faubel S, Lewis EC, Reznikov L, et al. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 322(1), 8-15 (2007). (Pubitemid 46956357)
44. Haq M, Norman J, Saba SR, Ramirez G, Rabb H. Role of IL-1 in renal ischemic reperfusion injury. J. Am. Soc. Nephrol. 9(4), 614-619 (1998).
45. Furuichi K, Wada T, Iwata Y, et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit. Care Med. 34(9), 2447-2455 (2006). (Pubitemid 44260032)
46. Kelly KJ, Williams WW Jr, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc. Natl Acad. Sci. USA 91(2), 812-816 (1994). (Pubitemid 24041492)
47. Rabb H, Mendiola CC, Dietz J, et al. Role of CD11a and CD11b in ischemic acute renal failure in rats. Am. J. Physiol. 267(6 Pt 2), F1052-F1058 (1994). (Pubitemid 124005387)
48. Haug CE, Colvin RB, Delmonico FL, et al. A Phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55(4), 766-772; discussion 772-773 (1993).
49. Salmela K, Wramner L, Ekberg H, et al. A randomized multicenter trial of the anti- ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 67(5), 729-736 (1999). (Pubitemid 29161715)
50. Takada M, Nadeau KC, Shaw GD, Tilney NL. Early cellular and molecular changes in ischemia/reperfusion injury: inhibition by a selectin antagonist, P-selectin glycoprotein ligand-1. Transplant. Proc. 29(1-2), 1324-1325 (1997). (Pubitemid 27126215)
51. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J. 14(1), 48-54 (2000). (Pubitemid 30051522)
52. Osama Gaber A, Mulgaonkar S, Kahan BD, et al. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin. Transplant. 25(4), 523-533 (2011).
53. Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 277(3 Pt 2), F404-F412 (1999). (Pubitemid 29459653)
54. Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J. Clin. Invest. 112(6), 883-891 (2003). (Pubitemid 38063746)
55. 4+ T cells and IFN-gamma. J. Immunol. 176(5), 3108-3114 (2006).
56. Rouschop KM, Roelofs JJ, Claessen N, et al. Protection against renal ischemia reperfusion injury by CD44 disruption. J. Am. Soc. Nephrol. 16(7), 2034-2043 (2005). (Pubitemid 41716434)
57. Li L, Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 120(1), 331-342 (2010).
58. Gao JL, Kuhns DB, Tiffany HL, et al. Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J. Exp. Med. 177(5), 1421-1427 (1993). (Pubitemid 23117132)
59. Pease JE, Horuk R. CCR1 antagonists in clinical development. Expert Opin. Investig. Drugs 14(7), 785-796 (2005). (Pubitemid 41030947)
60. Furuichi K, Wada T, Sakai N, et al. Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am. J. Nephrol. 20(4), 291-299 (2000).
61. Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 109(2), 251-259 (2002). (Pubitemid 34083745)
62. Vielhauer V, Berning E, Eis V, et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int. 66(6), 2264-2278 (2004). (Pubitemid 41115289)
63. Furuichi K, Gao JL, Horuk R, Wada T, Kaneko S, Murphy PM. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J. Immunol. 181(12), 8670-8676 (2008).
64. Furuichi K, Wada T, Iwata Y, et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J. Am. Soc. Nephrol. 14(10), 2503-2515 (2003). (Pubitemid 37169336)
65. Li L, Huang L, Sung SS, et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int. 74(12), 1526-1537 (2008).
66. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD. Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int. 71(7), 619-628 (2007). (Pubitemid 46494569)
67. Tadagavadi RK, Reeves WB. Renal dendritic cells ameliorate nephrotoxic acute kidney injury. J. Am. Soc. Nephrol. 21(1), 53-63 (2010).
68. Tadagavadi RK, Reeves WB. Endogenous IL-10 attenuates cisplatin nephrotoxicity: role of dendritic cells. J. Immunol. 185(8), 4904-4911 (2010).
69. Hayama T, Matsuyama M, Funao K, et al. Benefical effect of neutrophil elastase inhibitor on renal warm ischemia-reperfusion injury in the rat. Transplant. Proc. 38(7), 2201-2202 (2006). (Pubitemid 46068507)
70. Zhang ZX, Shek K, Wang S, et al. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J. Immunol. 185(2), 967-973 (2010).
71. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int. 67(2), 524-530 (2005). (Pubitemid 40139844)
72. Thurman JM, Royer PA, Ljubanovic D, et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 17(3), 707-715 (2006).
73. Thurman JM, Ljubanovic D, Royer PA, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J. Clin. Invest. 116(2), 357-368 (2006). (Pubitemid 43228352)
74. de Vries B, Walter SJ, Peutz-Kootstra CJ, Wolfs TG, van Heurn LW, Buurman WA. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am. J. Pathol. 165(5), 1677-1688 (2004). (Pubitemid 39435166)
75. Moller-Kristensen M, Wang W, Ruseva M, et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand. J. Immunol. 61(5), 426-434 (2005). (Pubitemid 40695013)
76. Zheng X, Zhang X, Sun H, et al. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 82(12), 1781-1786 (2006). (Pubitemid 46035667)
77. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63(1), 134-142 (2003). (Pubitemid 35463914)
78. Zheng X, Zhang X, Feng B, et al. Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am. J. Pathol. 173(4), 973-980 (2008).
79. Ichim TE, Li M, Qian H, et al. RNA interference: a potent tool for gene-specific therapeutics. Am. J. Transplant. 4(8), 1227-1236 (2004). (Pubitemid 39013568)
80. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol. 290(6), F1516-F1524 (2006). (Pubitemid 43830779)
81. Lien YH, Yong KC, Cho C, Igarashi S, Lai LW. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69(9), 1601-1608 (2006).
82. Bajwa A, Jo SK, Ye H, et al. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J. Am. Soc. Nephrol. 21(6), 955-965 (2010).
83. Park P, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am. J. Physiol. Renal Physiol. 282(2), F352-F357 (2002). (Pubitemid 34654567)
84. Burne-Taney MJ, Yokota-Ikeda N, Rabb H. Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. Am. J. Transplant. 5(6), 1186-1193 (2005). (Pubitemid 40839406)
85. Rabb H, Daniels F, O'Donnell M, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am. J. Physiol. Renal Physiol. 279(3), F525-F531 (2000).
86. Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest. 108(9), 1283-1290 (2001). (Pubitemid 33107755)
87. Yokota N, Burne-Taney M, Racusen L, Rabb H. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 285(2), F319-F325 (2003). (Pubitemid 36871205)
88. Yokota N, Daniels F, Crosson J, Rabb H. Protective effect of T cell depletion in murine renal ischemia-reperfusion injury. Transplantation 74(6), 759-763 (2002).
89. Sakr M, Zetti G, McClain C, et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation 53(5), 987-991 (1992).
90. Jones EA, Shoskes DA. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair. J. Urol. 163(3), 999-1004 (2000). (Pubitemid 30091677)
91. Chandraker A, Takada M, Nadeau KC, Peach R, Tilney NL, Sayegh MH. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int. 52(6), 1678-1684 (1997). (Pubitemid 28032075)
92. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J. Clin. Invest. 100(5), 1199-1203 (1997). (Pubitemid 27386305)
93. Burne-Taney MJ, Ascon DB, Daniels F, Racusen L, Baldwin W, Rabb H. B cell deficiency confers protection from renal ischemia reperfusion injury. J. Immunol. 171(6), 3210-3215 (2003). (Pubitemid 37093547)
94. Jang HR, Gandolfo MT, Ko GJ, Satpute SR, Racusen L, Rabb H. B cells limit repair after ischemic acute kidney injury. J. Am. Soc. Nephrol. 21(4), 654-665 (2010).
95. Hoste EA, Kellum JA. RIFLE criteria provide robust assessment of kidney dysfunction and correlate with hospital mortality. Crit. Care Med. 34(7), 2016-2017 (2006). (Pubitemid 43982486)
96. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin. J. Am. Soc. Nephrol. 2(2), 356-365 (2007).
97. McCune TR, Wombolt DG, Whelan TV, Thacker LR, Colonna JO. Vasodilatation vs. immunotherapy to prevent delayed graft function: delayed graft function as an indication of immune activation. Int. Immunopharmacol. 5(1), 85-92 (2005). (Pubitemid 39626688)
98. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N. Engl. J. Med. 355(19), 1967-1977 (2006). (Pubitemid 44708016)
99. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin. Nephrol. 62(4), 273-278 (2004). (Pubitemid 39386803)
100. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am. J. Med. 118(8), 843-849 (2005). (Pubitemid 41097461)
101. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am. Heart J. 155(3), 499.e1-499.e8 (2008).
102. Singh RP, Farney AC, Rogers J, et al. Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on post-transplant outcomes. Clin. Transplant. 25(2), 255-264 (2011).
103. Wells AC, Rushworth L, Thiru S, et al. Donor kidney disease and transplant outcome for kidneys donated after cardiac death. Br. J. Surg. 96(3), 299-304 (2009).
104. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J. Biol. Chem. 277(17), 15028-15034 (2002). (Pubitemid 34952579)
105. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 277(17), 15107-15112 (2002). (Pubitemid 34952589)
106. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279(9), 7370-7377 (2004). (Pubitemid 38294612)
107. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894), 191-195 (2002). (Pubitemid 34773774)
108. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957), 516-521 (2003). (Pubitemid 37237047)
109. Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J. Clin. Invest. 85(4), 1150-1157 (1990). (Pubitemid 20123757)
110. Hefeneider SH, Cornell KA, Brown LE, Bakke AC, McCoy SL, Bennett RM. Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. Clin. Immunol. Immunopathol. 63(3), 245-251 (1992).
111. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J. Immunol. 170(6), 3233-3242 (2003). (Pubitemid 36302201)
112. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464(7285), 104-107 (2010).
113. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 62(11), 1565-1570 (1996). (Pubitemid 27009911)
114. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a case-control study. Nephrol. Dial. Transplant. 17(11), 1936-1941 (2002). (Pubitemid 35277091)
115. Cravedi P, Codreanu I, Satta A, et al. Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer? Nephron Clin. Pract. 101(2), c65-c71 (2005). (Pubitemid 41208893)
116. Huang E, Cho YW, Hayashi R, Bunnapradist S. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 84(7), 821-828 (2007). (Pubitemid 351338941)